

Josã© Antonio da Silva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3727969/publications.pdf>

Version: 2024-02-01

202
papers

14,353
citations

71102

41
h-index

21540

114
g-index

211
all docs

211
docs citations

211
times ranked

14351
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment”. Annals of the Rheumatic Diseases, 2023, 82, e183-e183.	0.9	3
2	Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. Clinical Rheumatology, 2022, 41, 1069-1078.	2.2	5
3	Correspondence on “Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment” by Felson et al. ACR Open Rheumatology, 2022, 4, 271-272.	2.1	1
4	Reexamining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level, and patient global assessment: comment on the article by Felson et al. Arthritis Care and Research, 2022, 74, 501-502.	3.4	0
5	Ultrasound and elastography in the assessment of skin involvement in systemic sclerosis: A systematic literature review focusing on validation and standardization “ WSF Skin Ultrasound Group. Seminars in Arthritis and Rheumatism, 2022, 52, 1519-1524.	3.4	14
6	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1311-1321.	4.7	16
7	Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clinical and Experimental Research, 2022, 34, 2205-2215.	2.9	15
8	The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. Current Opinion in Rheumatology, 2022, 34, 179-186.	4.3	4
9	Treating-to-target in rheumatology: Theory and practice. Best Practice and Research in Clinical Rheumatology, 2022, 36, 1017-1035.	3.3	12
10	Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology, 2022, 61, 3309-3316.	1.9	14
11	Human Bone Marrow Mesenchymal Stromal/Stem Cells Regulate the Proinflammatory Response of Monocytes and Myeloid Dendritic Cells from Patients with Rheumatoid Arthritis. Pharmaceutics, 2022, 14, 404.	4.5	5
12	Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial. Frontiers in Aging, 2022, 3, .	2.6	13
13	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. Rheumatology, 2022, 62, 98-107.	1.9	1
14	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases, 2022, 81, 925-936.	0.9	59
15	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	3.1	33
16	Comment on: “It can’t be zero!” difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study: reply. Rheumatology, 2021, 60, e30-e31.	1.9	0
17	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.9	12
18	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Annals of the Rheumatic Diseases, 2021, 80, 293-303.	0.9	32

#	ARTICLE	IF	CITATIONS
19	Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. <i>Joint Bone Spine</i> , 2021, 88, 105071.	1.6	5
20	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. <i>Contemporary Clinical Trials</i> , 2021, 100, 106124.	1.8	28
21	Happiness, quality of life and their determinants among people with systemic sclerosis: a structural equation modelling approach. <i>Rheumatology</i> , 2021, 60, 4717-4727.	1.9	8
22	Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trials. <i>Age and Ageing</i> , 2021, 50, 1988-1996.	1.6	17
23	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study. <i>Rheumatology</i> , 2021, 60, 3334-3342.	1.9	13
24	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	3.8	10
25	Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. <i>Rheumatology</i> , 2021, 60, 5134-5141.	1.9	18
26	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e481-e488.	3.9	25
27	POS0055...SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 233-234.	0.9	1
28	EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. <i>RMD Open</i> , 2021, 7, e001684.	3.8	2
29	Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. <i>Journal of Rheumatology</i> , 2021, 48, 1763-1766.	2.0	8
30	Frequência de síndrome metabólica em estudantes de uma universidade pública brasileira. <i>Research, Society and Development</i> , 2021, 10, e37101219802.	0.1	0
31	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	3.4	8
32	High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation. <i>Joint Bone Spine</i> , 2021, 88, 105242.	1.6	17
33	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 186-193.	0.8	1
34	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 130, 120-127.	0.8	0
35	Dual-target strategy: fostering person-centered care in rheumatology. <i>Acta Reumatológica Portuguesa</i> , 2021, 46, 99-102.	0.2	1
36	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 120-127.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Editorial: Osteoporosis in Rheumatic Diseases, What's New?. <i>Frontiers in Medicine</i> , 2021, 8, 808345.	2.6	2
38	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 186-193.	0.8	29
39	Topical NSAIDs for chronic musculoskeletal pain in adults. <i>The Cochrane Library</i> , 2020, 2020, CD007400.	2.8	168
40	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 20-27.	2.0	3
41	Immunomodulatory effect of human bone marrow-derived mesenchymal stromal/stem cells on peripheral blood T cells from rheumatoid arthritis patients. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 16-28.	2.7	30
42	"It can't be zero!" Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2020, 59, 1137-1147.	1.9	19
43	Shared decision-making in people with chronic disease: Integrating the biological, social and lived experiences is a key responsibility of nurses. <i>Musculoskeletal Care</i> , 2020, 18, 84-91.	1.4	8
44	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	7.4	180
45	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. <i>Rheumatology</i> , 2020, 59, 3458-3467.	1.9	6
46	How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography. <i>Arthritis Research and Therapy</i> , 2020, 22, 50.	3.5	13
47	Prevalence of vitamin D deficiency and its predictors in the Portuguese population: a nationwide population-based study. <i>Archives of Osteoporosis</i> , 2020, 15, 36.	2.4	22
48	Progress towards improved non-pharmacological management of fibromyalgia. <i>Joint Bone Spine</i> , 2020, 87, 377-379.	1.6	11
49	Recent Patents on Impact of Lipopeptide on the Biofilm Formation onto Titanium and Stainless Steel Surfaces. <i>Recent Patents on Biotechnology</i> , 2020, 14, 49-62.	0.8	10
50	Patient global assessment and radiographic progression in early arthritis: 3-year results from the ESPOIR cohort. <i>Arthritis Care and Research</i> , 2020, 73, 1300-1305.	3.4	9
51	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
52	The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 583-585.	3.4	18
53	THU0586...ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 535.1-535.	0.9	1
54	AB0179...BEYOND DISEASE ACTIVITY, PAIN, "TIME" AND "TIMING" ACCOUNT FOR DISABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A REAL-LIFE COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1389-1389.	0.9	0

#	ARTICLE	IF	CITATIONS
55	SAT0184â€¦...MAINTENANCE THERAPY WITH AZATHIOPRINE ASSOCIATED WITH HIGHER RISK OF FLARE IN PROLIFERATIVE LUPUS NEPHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1033-1034.	0.9	0
56	Educational needs in people with ankylosing spondylitis and psoriatic arthritis: a cross-sectional study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 282-288.	0.8	1
57	Depression, disability and sleep disturbance are the main explanatory factors of fatigue in rheumatoid arthritis: a path analysis model. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 314-321.	0.8	7
58	Ultrasonography for the Assessment of Skin in Systemic Sclerosis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019, 71, 563-574.	3.4	39
59	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 695-696.	3.4	1
60	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.9	35
61	The impact of fatigue in rheumatoid arthritis and the challenges of its assessment. <i>Rheumatology</i> , 2019, 58, v3-v9.	1.9	29
62	Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 340-341.	1.1	1
63	205â€œFrom zero to ten: difficulties in completing patient global assessment in rheumatoid arthritis: a mixed-methods study. <i>Rheumatology</i> , 2019, 58, .	1.9	0
64	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019, 71, 1317-1325.	3.4	41
65	FRIO123â€¦...BIOLOGICAL THERAPIES SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTSIN CLINICAL PRACTICE: RESULTS FROM THE METEOR REGISTRY. , 2019, , .		0
66	Effectiveness of non-pharmacological and non-surgical interventions for rheumatoid arthritis: an umbrella review. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 1494-1531.	1.7	28
67	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
68	Effectiveness of non-pharmacological and non-surgical interventions on the impact of rheumatoid arthritis. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 22-27.	1.7	4
69	Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 365-371.	0.9	88
70	The impact of transducer frequency in ultrasound evaluation of subclinical skin involvement in limited cutaneous systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 147-148.	0.8	2
71	Validation of Rheumatoid Arthritis Quality of Life (RAQoL) Questionnaire into Portuguese Language. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2019, 44, 65-70.	0.2	0
72	Glucocorticoids Are Always Under Suspicion â€” Is the Perception of Their Risks Unbiased?. <i>Journal of Rheumatology</i> , 2018, 45, 293-296.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Influence of the different "patient global assessment" formulations on disease activity score by different indices in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 1963-1969.	2.2	14
74	Just a painful swelling of the ankles?. <i>BMJ: British Medical Journal</i> , 2018, 360, k436.	2.3	0
75	Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 360-363.	1.1	7
76	Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212934.	0.9	19
77	Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. <i>Lupus</i> , 2018, 27, 1358-1362.	1.6	27
78	The controversy of using PGA to define remission in RA. <i>Nature Reviews Rheumatology</i> , 2018, 14, 245-245.	8.0	5
79	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	3.4	84
80	Preventing progression from arthralgia to arthritis: targeting the right patients. <i>Nature Reviews Rheumatology</i> , 2018, 14, 32-41.	8.0	91
81	Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients. <i>Inflammation Research</i> , 2018, 67, 169-177.	4.0	28
82	The leopard woman: a subacute and rare presentation. <i>Rheumatology</i> , 2018, 57, 428-428.	1.9	0
83	OPO160-HPR...Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach. , 2018, , .		0
84	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
85	The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. <i>Quality of Life Research</i> , 2018, 27, 2909-2921.	3.1	8
86	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. <i>Frontiers in Medicine</i> , 2018, 5, 40.	2.6	26
87	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 67.	1.6	32
88	The many faces of IgG4-related disease: report of a case with inaugural recurrent aortic aneurism ruptures and literature review. <i>Rheumatology International</i> , 2018, 38, 1565-1570.	3.0	5
89	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
90	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. <i>Acta Reumatológica Portuguesa</i> , 2018, 43, 52-60.	0.2	5

#	ARTICLE	IF	CITATIONS
91	Systemic oxalosis in hyperoxaluria type 1. <i>Rheumatology</i> , 2017, 56, kew380.	1.9	0
92	EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 802-810.	0.9	111
93	Invalidation in Patients with Rheumatic Diseases: Clinical and Psychological Framework. <i>Journal of Rheumatology</i> , 2017, 44, 512-518.	2.0	31
94	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
95	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	1.9	71
96	Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. <i>RMD Open</i> , 2017, 3, e000509.	3.8	18
97	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	2.0	15
98	Chronic widespread pain and increased mortality: biopsychosocial interconnections. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-211893.	0.9	9
99	OP0144-HPR can't be zero: a qualitative study of patients' perspective on patient global assessment in rheumatoid arthritis. , 2017, , .		2
100	Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. <i>Acta Reumatol3gica Portuguesa</i> , 2017, 42, 55-65.	0.2	4
101	Can health care providers recognise a fibromyalgia personality?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 43-49.	0.8	1
102	General Practitioners and Rheumatologists: new bridges for a successful cooperation. <i>Acta Reumatol3gica Portuguesa</i> , 2017, 42, 6-7.	0.2	1
103	The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update. <i>Acta Reumatol3gica Portuguesa</i> , 2017, 42, 219-228.	0.2	4
104	Unilateral calf hypertrophy and radiculopathy: an unusual association. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217744.	0.5	3
105	Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review. <i>Arthritis Research and Therapy</i> , 2016, 18, 153.	3.5	12
106	Subset-specific alterations in frequencies and functional signatures of ð³ T cells in systemic sclerosis patients. <i>Inflammation Research</i> , 2016, 65, 985-994.	4.0	15
107	AB1069...The Educational Needs of People with Spondyloarthropathies (AS and PSA): A Cross-Sectional Study: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1267.2-1267.	0.9	0
108	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016, 18, 213.	3.5	19

#	ARTICLE	IF	CITATIONS
109	CD38, CD81 and BAFFR combined expression by transitional B cells distinguishes active from inactive systemic lupus erythematosus. <i>Clinical and Experimental Medicine</i> , 2016, 16, 227-232.	3.6	16
110	Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal. <i>Calcified Tissue International</i> , 2016, 99, 131-141.	3.1	25
111	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 795-810.	0.9	780
112	The prevalence of severe fatigue in rheumatic diseases: an international study. <i>Clinical Rheumatology</i> , 2016, 35, 409-415.	2.2	147
113	A preliminary study using virtual touch imaging and quantification for the assessment of skin stiffness in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 137-141.	0.8	14
114	Multidisciplinary Portuguese recommendations on DXA request and indication to treat in the prevention of fragility fractures. <i>Acta Reumatológica Portuguesa</i> , 2016, 41, 305-321.	0.2	1
115	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 349-354.	0.9	7
116	The importance of heat against antinutritional factors from <i>Chenopodium quinoa</i> seeds. <i>Food Science and Technology</i> , 2015, 35, 74-82.	1.7	7
117	TRAF1/C5 but Not PTPRC Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	15
118	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	19
119	Kyphoscoliosis: looking beyond the spine. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014209096-bcr2014209096.	0.5	0
120	Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets. <i>Journal of Inflammation</i> , 2015, 12, 38.	3.4	8
121	Outcome Measures in Polymyalgia Rheumatica. A Systematic Review. <i>Journal of Rheumatology</i> , 2015, 42, 2503-2511.	2.0	14
122	Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. <i>Lupus</i> , 2015, 24, 256-262.	1.6	26
123	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1183-1187.	0.9	18
124	The burden of osteoporotic hip fractures in Portugal: costs, health related quality of life and mortality. <i>Osteoporosis International</i> , 2015, 26, 2623-2630.	3.1	54
125	Operational Definition of Active and Healthy Aging (AHA): The European Innovation Partnership (EIP) on AHA Reference Site Questionnaire: Montpellier October 2014-2015, Lisbon July 2, 2015. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1020-1026.	2.5	33
126	The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1958-1967.	0.9	128

#	ARTICLE	IF	CITATIONS
127	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	2.5	13
128	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	1.9	23
129	CD8+ T Cell Profiles in Patients With Rheumatoid Arthritis and Their Relationship to Disease Activity. <i>Arthritis and Rheumatology</i> , 2015, 67, 363-371.	5.6	67
130	Safety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials. <i>NeuroImmunoModulation</i> , 2015, 22, 57-65.	1.8	18
131	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015, 54, 286-291.	1.9	22
132	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 110-24.	0.2	26
133	Milwaukee shoulder (and knee) syndrome. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202183-bcr2013202183.	0.5	8
134	Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR. <i>Journal of Rheumatology</i> , 2014, 41, 819-823.	2.0	28
135	Safety of low to medium dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 41-49.	3.8	26
136	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	1.9	8
137	Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. <i>Rheumatology</i> , 2014, 53, 85-89.	1.9	45
138	Measurement invariance of the Illness Invalidation Inventory (3*) across language, rheumatic disease and gender. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 551-556.	0.9	19
139	Coexisting primary Sjögren's syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome?. <i>Rheumatology International</i> , 2014, 34, 1619-1622.	3.0	16
140	THU0593-HPR...Severe Fatigue is Highly Prevalent in ALL Rheumatic Diseases: an International Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1197.3-1198.	0.9	0
141	Exercise-induced Pulmonary Hypertension in Scleroderma Patients: A Common Finding but with Elusive Pathophysiology. <i>Echocardiography</i> , 2013, 30, 378-384.	0.9	10
142	A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF- α agent?. <i>Clinical Rheumatology</i> , 2013, 32, 1819-1822.	2.2	20
143	EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1125-1135.	0.9	1,033
144	EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1905-1913.	0.9	220

#	ARTICLE	IF	CITATIONS
145	Assessment of cardiovascular risk in rheumatoid arthritis patients. <i>European Journal of Internal Medicine</i> , 2013, 24, e135-e136.	2.2	0
146	Distribution and functional plasticity of peripheral blood Th(c)17 and Th(c)1 in rheumatoid arthritis. <i>Rheumatology International</i> , 2013, 33, 2093-2099.	3.0	17
147	Potential roles for CD8+ T cells in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013, 12, 401-409.	5.8	78
148	NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. <i>Clinical Rheumatology</i> , 2013, 32, 805-813.	2.2	69
149	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 121.	3.3	0
150	Developing a professional approach to work-based assessments in rheumatology. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 123-136.	3.3	5
151	A10.5â€¦Comparative Effectiveness of Biological Therapies in Rheumatoid Arthritis is Influenced by Response Measures and Disease Activity State. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A73.1-A73.	0.9	0
152	FRIO096â€¦Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A402.1-A402.	0.9	0
153	A FRAX model for the estimation of osteoporotic fracture probability in Portugal. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2013, 38, 104-12.	0.2	5
154	Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 2020-2026.	1.9	78
155	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012, 14, R37.	3.5	41
156	Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus. <i>Rheumatology International</i> , 2012, 32, 863-869.	3.0	46
157	Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues. <i>Clinical Rheumatology</i> , 2012, 31, 483-491.	2.2	9
158	Clarifications needed, please. <i>BMJ: British Medical Journal</i> , 2011, 342, d2602-d2602.	2.3	2
159	European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 722-726.	0.9	208
160	Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 6-11.	1.1	44
161	Rheumatology education in Europe: results of a survey of young rheumatologists. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 843-5.	0.8	16
162	Selecting men for bone densitometry: performance of osteoporosis risk assessment tools in Portuguese men. <i>Osteoporosis International</i> , 2010, 21, 977-983.	3.1	15

#	ARTICLE	IF	CITATIONS
163	Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus. <i>Cellular Immunology</i> , 2010, 264, 97-103.	3.0	82
164	Prediction of Vertebral Fractures Is Specific for Gender and Site of Bone Mineral Density Measurement. <i>Journal of Rheumatology</i> , 2010, 37, 149-154.	2.0	6
165	Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010, 12, 220.	3.5	14
166	Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1015-1021.	0.9	117
167	Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1913-1919.	0.9	159
168	Patients- and physicians- priorities for improvement. The case of rheumatic diseases. <i>Acta Reumatológica Portuguesa</i> , 2010, 35, 192-9.	0.2	10
169	Competencies in rheumatology: a European framework. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 145-160.	3.3	8
170	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 125.	3.3	0
171	Influência do perfil lipídico em placas ateroscleróticas coronarianas moderadas: análise com ultrassom intracoronariano. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2009, 17, 88-93.	0.1	0
172	Topical diclofenac and its role in pain and inflammation: an evidence-based review. <i>Current Medical Research and Opinion</i> , 2008, 24, 925-950.	1.9	93
173	Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 229-240.	0.1	0
174	EULAR evidence-based recommendations for the management of fibromyalgia syndrome. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 536-541.	0.9	639
175	A questionnaire for listening to students' voices in the assessment of teaching quality in a classical medical school. <i>Assessment and Evaluation in Higher Education</i> , 2008, 33, 445-453.	5.6	2
176	UEMS charter on the training of rheumatologists in Europe. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 555-558.	0.9	11
177	Performance of decision algorithms for the identification of low bone mineral density in Portuguese postmenopausal women. <i>Acta Reumatológica Portuguesa</i> , 2008, 33, 314-28.	0.2	4
178	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1560-1567.	0.9	325
179	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 285-293.	0.9	402
180	Effects of Testosterone, 17beta-Estradiol, and Downstream Estrogens on Cytokine Secretion from Human Leukocytes in the Presence and Absence of Cortisol. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 168-182.	3.8	56

#	ARTICLE	IF	CITATIONS
181	Revisiting the Toxicity of Low-Dose Glucocorticoids: Risks and Fears. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 275-288.	3.8	19
182	Soft tissue injections. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 503-527.	3.3	16
183	Developments in Glucocorticoid Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 1-17.	1.9	34
184	The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 14-21.	1.1	107
185	Cervical complications of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 355-358.	0.9	15
186	EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1172-1176.	0.9	183
187	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 718-722.	0.9	395
188	Differential Male and Female Adrenal Cortical Steroid Hormone and Cortisol Responses to Interleukin-6 in Humans. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 68-72.	3.8	18
189	Relationships between Glucocorticoids and Gonadal Steroids in Rheumatoid Arthritis. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 158-165.	3.8	8
190	Destruction of articular cartilage by alpha2 macroglobulin elastase complexes: role in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 109-113.	0.9	31
191	Sex Hormones and Glucocorticoids: Interactions with the Immune System. <i>Annals of the New York Academy of Sciences</i> , 1999, 876, 102-118.	3.8	234
192	Gender Differences in Adrenal and Gonadal Responses to Inflammatory Aggression. <i>Annals of the New York Academy of Sciences</i> , 1999, 876, 148-151.	3.8	7
193	Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis. <i>Bailliere's Clinical Rheumatology</i> , 1996, 10, 295-332.	1.0	50
194	A RANDOMIZED TRIAL OF TESTOSTERONE THERAPY IN MALES WITH RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 1996, 35, 568-573.	1.9	81
195	Sex steroids affect glucocorticoid response to chronic inflammation and to interleukin-1. <i>Journal of Endocrinology</i> , 1993, 136, 389-397.	2.6	56
196	Protective effect of androgens against inflammation induced cartilage degradation in male rodents. <i>Annals of the Rheumatic Diseases</i> , 1993, 52, 285-291.	0.9	25
197	Pregnancy and Rheumatoid Arthritis: An Overview. <i>American Journal of Reproductive Immunology</i> , 1992, 28, 222-225.	1.2	26
198	The role of pregnancy in the course and aetiology of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 1992, 11, 189-194.	2.2	165

#	ARTICLE	IF	CITATIONS
199	The effects of gender and sex hormones on outcome in rheumatoid arthritis. Bailliere's Clinical Rheumatology, 1992, 6, 193-219.	1.0	77
200	Heat shock proteins: the missing link between hormonal and reproductive factors and rheumatoid arthritis?. Annals of the Rheumatic Diseases, 1991, 50, 735-739.	0.9	10
201	JOINT SPACE IN RADIOLOGICALLY NORMAL KNEES. Rheumatology, 1991, 30, 426-428.	1.9	38
202	Predictors of hospitalization in patients with systemic lupus erythematosus: a 10-year cohort study. Clinical Rheumatology, 0, , .	2.2	3